Fissios and postoperative complications (FPoC trial): a multicentre, randomised, controlled clinical trial Authors: Carlos Alfredo Fraile Olivero, Lidia Sotillo Valenzuela, Verónica Albarrán Vidal, José Gabriel Barceló Cal, Verónica Alen Villamayor, Florentino Hernando Trancho, Elena Fernández Martín, Joaquín Calatayud Gastardi, Ana María Gómez Martínez, Pedro Daniel Arribas Manzanal, Passio Santos, Raquel Fernández Blanco, María Isabel Cal Vázquez, Lucia Milla Collado, María Rodríguez, Valerio Perna, Alejandra Romero Roman, Carlos Andrés Ordonez, José Ramón Jarabo Sarceda Published: 2026 ABSTRACT AbstractIntroductionRespiratory physiotherapy as a part of a perioperative physical training programme may reduce the risk of developing postoperative complications in patients diagnosed with non-small cell lung carcinoma (NSCLC) scheduled for surgery. However, there is heterogeneity in the design, implementation and evaluation of respiratory physiotherapy programmes.Fissios App contains a standardised respiratory physiotherapy programme. Analysing the usage data, the patient’s personal history, the surgical procedure and the postoperative course, we will establish the relationship between compliance with a standardised respiratory physiotherapy programme and the development of postoperative complications in a group of patients diagnosed with NSCLC who underwent lung resection surgery.Methods and analysisThe Fissios and postoperative cpostoperative complications trial is a multicentre, prospective, randomised, parallel two-group, controlled, open-label, superiority study of the use of only face-to-face respiratory physiotherapy or the use of Fissios App as a complement to respiratory physiotherapy. Based on the percentage of postoperative respiratory complications and the anticipated reduction, a total of 560 patients will be required. Patients will be electronically randomised to the intervention or control group before the surgery with a proportion of 1:1 in blocks of six for each centre.All patients will attend face-to-face respiratory physiotherapy sessions at the place and times established in each centre. In addition, patients in the intervention group will use the Fissios App freely and without restrictions in terms of hour of the day, usage time or location. The primary clinical endpoint is postoperative complications during hospital admission and the estimated duration of the study is 12 months.Ethics and disseminationThis protocol was reviewed and approved by the Clinical Research and Clinical Trials Unit of Hospital Clínico San Carlos (Madrid, Spain) and complies with the ethics principles for medical research on humans stipulated in the Declaration of Helsinki of the World Medical Association.Trial registration numberNCT06732193.Keywords: Thoracic Surgery, Telemedicine, Pulmonary Rehabilitation, Non-Small Cell Lung Cancer, Lung Cancer, Exercise, Respiratory Muscles WHAT IS ALREADY KNOWN ON THIS TOPIC WHAT THIS STUDY ADDS The implementation of a standardised and detailed respiratory physiotherapy programme in a selected group of 560 patients scheduled for lung resection surgery to improve postoperative outcomes. The implementation of a standardised and detailed respiratory physiotherapy programme in a selected group of 560 patients scheduled for lung resection surgery to improve postoperative outcomes. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY The use of Fissios App as a complement to a face-to-face respiratory physiotherapy programme may reduce postoperative complications. The use of Fissios App as a complement to a face-to-face respiratory physiotherapy programme may reduce postoperative complications. Introduction Background and rationale Respiratory physiotherapy as a part of a preoperative physical training programme may reduce the risk of developing postoperative complications, thereby improving postoperative results and optimising the physical condition of patients diagnosed with non-small cell lung carcinoma (NSCLC) undergoing lung resection surgery.1 2 During the postoperative period, performing physical exercise has also been shown to increase the capacity for exercise, improve health-related quality of life and reduce the feeling of breathlessness.3 However, these findings should be interpreted with caution due to disparities between the studies and the risk of bias. The numerous respiratory physiotherapy protocols available vary by type of exercise, duration, repetition, intensity and modality (outpatient or under specialised personal supervision). There is also variability when measuring the results of the protocol. Some studies report a reduction in respiratory complications or hospital stay,2 4 while others only demonstrate improvements in the physical condition or quality of life of patients.5 The heterogeneity in the design, implementation and evaluation of physiotherapy programmes makes it difficult to demonstrate their effectiveness or to generalise their real-life benefits.6 Further studies are needed with larger samples and better methodological quality to clarify the potential benefits of perioperative physical training in NSCLC patients.7 Fissios App, a software tool developed by thoracic surgeons, physiotherapists and a specialist doctor in physical medicine and rehabilitation, has been successfully used with thoracic surgery patients.8 It contains a programme of standardised respiratory physiotherapy exercises with a defined time and number of repetitions. The possibility of recording individual patient usage time of the app and the degree of compliance with the programme is also offered on the Fissios Research platform.9 The usage data are complemented with the patient’s personal history, the surgical procedure performed and the postoperative course. With all the information centralised in a single platform, the aim is to establish the relationship between compliance with a standardised respiratory physiotherapy programme, postoperative outcomes and the development of postoperative complications in a group of patients diagnosed with NSCLC who underwent lung resection surgery. Fundamental rationale for the study Most thoracic surgeons prescribe respiratory physiotherapy exercises before and after surgery. However, studies published on the topic present various unresolved issues, including interinstitutional variability, a lack of homogeneity in the respiratory physiotherapy exercises, low sample numbers and surgical patients from different specialties. Therefore, there is an urgent need to perform clinical trials with protocolised exercise programmes applied to a carefully selected population of patients in order to strengthen the current evidence. Objectives Hypothesis The use of the technological tool Fissios App as a complement to a respiratory physiotherapy programme improves postoperative outcomes and reduces postoperative complications in comparison with patients who only undertake a face-to-face respiratory physiotherapy programme. Main aim To compare the effectiveness of the use of Fissios App as a complement to a perioperative respiratory physiotherapy programme versus the use of only a face-to-face perioperative respiratory physiotherapy programme in reducing the incidence of postoperative complications for patients diagnosed with NSCLC undergoing lung resection surgery. Secondary aims To ascertain the rate of treatment compliance with a perioperative respiratory physiotherapy programme. To ascertain the rate of treatment compliance with a perioperative respiratory physiotherapy programme. To quantify the total usage time of the Fissios App tool. To quantify the total usage time of the Fissios App tool. To quantify compliance with performing the respiratory physiotherapy exercises included in the Fissios App tool. To quantify compliance with performing the respiratory physiotherapy exercises included in the Fissios App tool. To quantify compliance with the reading of the perioperative medical recommendations included in the Fissios App tool. To quantify compliance with the reading of the perioperative medical recommendations included in the Fissios App tool. To determine the preoperative risk of developing a postoperative complication. To determine the preoperative risk of developing a postoperative complication. To describe the surgical procedure performed. To describe the surgical procedure performed. To record the development of postoperative complications. To record the development of postoperative complications. To quantify the duration of pleural drainage during the postoperative period. To quantify the duration of pleural drainage during the postoperative period. To quantify hospital stay duration. To quantify hospital stay duration. To record the need for hospital readmission associated with the surgical procedure during the first 30 postoperative days. To record the need for hospital readmission associated with the surgical procedure during the first 30 postoperative days. To record survival at 30 postoperative days. To record survival at 30 postoperative days. To record survival at 90 postoperative days. To record survival at 90 postoperative days. To compare the postoperative course of patients from the experimental and control groups. To compare the postoperative course of patients from the experimental and control groups. To establish the relationship between the use of the Fissios App tool and the development of postoperative complications. To establish the relationship between the use of the Fissios App tool and the development of postoperative complications. Trial design The Fissios and postoperative cpostoperative complications (FPoC) trial is designed as a multicentre, prospective, randomised, parallel, two-group, controlled, open-label, superiority study of the use of only face-to-face respiratory physiotherapy or the use of Fissios App as a complement to respiratory physiotherapy in patients scheduled for lung resection surgery. To guarantee homogeneity in the respiratory physiotherapy treatment that the patient will receive, the study will be performed in tertiary hospitals in Spain that jointly offer thoracic surgery and physiotherapy and rehabilitation services. Patients taking part in the study will be randomly assigned to the experimental or control group before the surgery. All patients will undertake a face-to-face respiratory physiotherapy programme, while those in the experimental group will complement this programme with use of the Fissios App tool. Perioperative care will be performed in accordance with national and international recommendation guidelines.10 11 Postoperative complications will be recorded following the definitions set out in the European Society of Thoracic Surgeons (ESTS) database and in this protocol.12 Finally, there will be a 90-day follow-up period following the date of surgery, with the patient receiving check-ups according to the protocols of each centre. Methods Study setting Tertiary hospitals in Spain. Eligibility criteria Eligibility criteria for the center The study is open to all tertiary hospitals in Spain that jointly offer thoracic surgery and physiotherapy and rehabilitation services. The study is open to all tertiary hospitals in Spain that jointly offer thoracic surgery and physiotherapy and rehabilitation services. The Department of Physiotherapy and Rehabilitation must have a circuit/protocol to perform face-to-face perioperative respiratory physiotherapy for patients undergoing a scheduled surgical procedure. The Department of Physiotherapy and Rehabilitation must have a circuit/protocol to perform face-to-face perioperative respiratory physiotherapy for patients undergoing a scheduled surgical procedure. The hospital should have clinical histories in paper or electronic format that are easy to access for the investigator to consult the preoperative evaluation and postoperative clinical course of the participating patients. The hospital should have clinical histories in paper or electronic format that are easy to access for the investigator to consult the preoperative evaluation and postoperative clinical course of the participating patients. Eligibility criteria for the department of thoracic surgery Departments willing to undertake the following will be considered for participation: Preoperative evaluation of all patients according to the European Respiratory Society/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemoradiotherapy).13 The investigator must record 14 preoperative variables, including calculation of predicted postoperative ppoDLCO (%) and ppoFEV1 (%), to obtain the EuroLung risk score. Preoperative evaluation of all patients according to the European Respiratory Society/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemoradiotherapy).13 The investigator must record 14 preoperative variables, including calculation of predicted postoperative ppoDLCO (%) and ppoFEV1 (%), to obtain the EuroLung risk score. Description of the surgical procedure performed. The investigator must record seven surgery variables, including the type of resection according to the residual tumour descriptors of the International Association for the Study of Lung Cancer (IASLC).14 Description of the surgical procedure performed. The investigator must record seven surgery variables, including the type of resection according to the residual tumour descriptors of the International Association for the Study of Lung Cancer (IASLC).14 Perioperative management of patients in accordance with national and international guidelines10 11 and a 90-day postoperative follow-up period. Postoperative complications are defined according to the ESTS database.12 The investigator must record seven postoperative variables. Perioperative management of patients in accordance with national and international guidelines10 11 and a 90-day postoperative follow-up period. Postoperative complications are defined according to the ESTS database.12 The investigator must record seven postoperative variables. Undertaking of the participating investigator to record all variables on the electronic case report form (eCRF). Undertaking of the participating investigator to record all variables on the electronic case report form (eCRF). Interest and enthusiasm of the investigator to work with an e-Health project and familiarity with the use of computer tools and database managers. Interest and enthusiasm of the investigator to work with an e-Health project and familiarity with the use of computer tools and database managers. Inclusion criteria Patients aged over 18 years. Patients aged over 18 years. Indication of lung resection surgery with diagnostic suspicion or histopathological diagnosis of NSCLC. Indication of lung resection surgery with diagnostic suspicion or histopathological diagnosis of NSCLC. Anatomical lung resection surgery: anatomical segmentectomy, lobectomy or pneumonectomy. Conventional or minimally invasive approach: Video Assisted Thoracic Surgery (VATS) and Robotic Assisted Thoracic Surgery (RATS). Anatomical lung resection surgery: anatomical segmentectomy, lobectomy or pneumonectomy. Conventional or minimally invasive approach: Video Assisted Thoracic Surgery (VATS) and Robotic Assisted Thoracic Surgery (RATS). Access to a smart mobile device compatible with the Fissios App tool, and the capacity or sufficient support to use it. Access to a smart mobile device compatible with the Fissios App tool, and the capacity or sufficient support to use it. Willingness and commitment to take part in the study. Willingness and commitment to take part in the study. Capacity to fill in the informed consent form to take part in the study. Capacity to fill in the informed consent form to take part in the study. Exclusion criteria Medical contraindication to perform preoperative and/or postoperative respiratory physiotherapy exercises. (Absolute contraindications: pneumothorax without a chest tube; pleural effusion with clinical repercussions and without a chest tube; moderate-to-severe subcutaneous emphysema; active haemoptysis; haemodynamic shock; uncontrolled cardiac arrhythmias; elevated intracranial pressure above 25 mmHg; sedation and analgesia in a critically ill patient; bronchospasm; pulmonary thromboembolism; suspected bronchial stump dehiscence. Relative contraindications: cognitive impairment; acute heart failure; unstable angina; uncontrolled epilepsy). Medical contraindication to perform preoperative and/or postoperative respiratory physiotherapy exercises. (Absolute contraindications: pneumothorax without a chest tube; pleural effusion with clinical repercussions and without a chest tube; moderate-to-severe subcutaneous emphysema; active haemoptysis; haemodynamic shock; uncontrolled cardiac arrhythmias; elevated intracranial pressure above 25 mmHg; sedation and analgesia in a critically ill patient; bronchospasm; pulmonary thromboembolism; suspected bronchial stump dehiscence. Relative contraindications: cognitive impairment; acute heart failure; unstable angina; uncontrolled epilepsy). No access to a smart mobile device compatible with the Fissios App tool. No access to a smart mobile device compatible with the Fissios App tool. Incapacity to perform exercises because of either a physical or mental impediment. Incapacity to perform exercises because of either a physical or mental impediment. Incapacity to fill in the informed consent form to take part in the study. Incapacity to fill in the informed consent form to take part in the study. Unwillingness to take part in the study. Unwillingness to take part in the study. Interventions Intervention description Intervention in the control group Perioperative respiratory physiotherapy will be prescribed after assessment by the investigator. The patient will attend an evaluation by a specialist doctor in respiratory rehabilitation and physiotherapy who will prescribe the exercises to be performed. The patient will attend face-to-face respiratory physiotherapy sessions given by physiotherapists before and after surgery at the place and times established in each centre, undertaking at least one session and with no limit on the number of sessions. Investigators will encourage the patient to attend and undergo face-to-face physiotherapy sessions and must record their attendance and degree of compliance on the eCRF. The study team will draw up a protocol with the minimum number of respiratory physiotherapy exercises that should be performed to guarantee treatment homogeneity between the control group and the experimental group (online supplemental material 4). The investigator will fill in the preoperative, surgery and postoperative data for each patient on the Fissios Research platform. Intervention in the experimental group The same protocol as in the control group will be applied in the experimental group and, in addition, the steps to download and implement the application will be explained to the participant (online supplemental material 3). The investigator will provide a unique registry code that the patient must enter in the application to activate their participation in the study. If possible, this should be done on the same day as the consultation. The investigator will encourage the patient to use the Fissios App tool freely and without restrictions in terms of hour of the day, usage time or location, to read all the perioperative medical recommendations and to perform the respiratory physiotherapy exercises. All Fissios App usage data will be automatically stored on the Fissios Research platform. The investigator will fill in the preoperative, surgery and postoperative data for each patient on the Fissios Research platform. Description of the health product Fissios is a computerised, interactive application developed by doctors and physiotherapists with the aim of reducing the probability of developing postoperative respiratory complications. It comprises 40 perioperative recommendations and a programme of 10 respiratory physiotherapy exercises. The recommendations, in the form of advice, are intended to inform the patient about basic aspects that contribute to the perioperative course. These include stopping smoking, oral hygiene and physical exercises. The respiratory physiotherapy exercises are explained with animations and are aimed at strengthening the respiratory muscles, promoting coughing and the mobilisation of secretions (figure 1). The Fissios App tool is a native 22 MB application developed using Ionic Framework V.3, Angular and Cordova technologies. Screenshots of two respiratory physiotherapy exercises contained in the Fissios App. Adherence Patients in the experimental group that configure and personalise the Fissios App tool will receive a notification on their mobile device 15 days before and after surgery at 10:00. These notifications contain perioperative recommendations and messages to positively strengthen the patient’s attitude. The intention of these notifications is to increase the patient’s interaction with the application and, indirectly, adherence to the interventions. To monitor adherence to the intervention, investigators can consult, via the Fissios Research platform, the participant’s usage time of the Fissios App tool, their compliance in terms of performing the exercises and whether the recommendations have been read. Notifications sent to the mobile device and the ability to monitor usage of the application are some of the advantages of new technologies in medicine that we aim to highlight in this study. Concomitant care Patients from both groups are permitted to receive other perioperative treatments to reduce the risk of developing postoperative complications. Outcomes Primary clinical endpoint Postoperative complications Recorded as the onset of at least one adverse clinical event categorised as a postoperative complication during hospital admission, measured at the time of hospital discharge. This endpoint is chosen because the onset of complications during the postoperative period increases the morbidity and mortality associated with the surgical procedure, and respiratory physiotherapy programmes can reduce the risk of developing these complications. Air leak >5 days: patient experienced a postoperative air leak for >5 days. Air leak >5 days: patient experienced a postoperative air leak for >5 days. Bronchoscopy for atelectasis: clinically or radiographically documented postoperative atelectasis that needed bronchoscopy. Bronchoscopy for atelectasis: clinically or radiographically documented postoperative atelectasis that needed bronchoscopy. Pneumonia: defined according to the most recent Center for Disease Control and Prevention (CDC) criteria: two or more serial chest radiographs with at least one of the following:New or progressive and persistent infiltrate.Consolidation.Cavitation.and at least one of the following:Fever (>38°C or >100.4°F) with no other recognised cause.Leucopenia (<4000 WBC/mm3) or leucocytosis (≥12000 WBC/mm3).For adults ≥70 years old, altered mental status with no other recognised cause.and at least two of the following:New onset of purulent sputum or change in character of sputum or increased respiratory secretions or increased suctioning requirements.New onset or worsening cough or dyspnoea or tachypnoea.Rales or bronchial breath sounds.Worsening gas exchange (eg, O2 desaturations (eg, PaO2/FiO2≤240), increased oxygen requirements or increased ventilator demand). Pneumonia: defined according to the most recent Center for Disease Control and Prevention (CDC) criteria: two or more serial chest radiographs with at least one of the following: New or progressive and persistent infiltrate. New or progressive and persistent infiltrate. Consolidation. Consolidation. Cavitation. Cavitation. and at least one of the following: Fever (>38°C or >100.4°F) with no other recognised cause. Fever (>38°C or >100.4°F) with no other recognised cause. Leucopenia (<4000 WBC/mm3) or leucocytosis (≥12000 WBC/mm3). Leucopenia (<4000 WBC/mm3) or leucocytosis (≥12000 WBC/mm3). For adults ≥70 years old, altered mental status with no other recognised cause. For adults ≥70 years old, altered mental status with no other recognised cause. and at least two of the following: New onset of purulent sputum or change in character of sputum or increased respiratory secretions or increased suctioning requirements. New onset of purulent sputum or change in character of sputum or increased respiratory secretions or increased suctioning requirements. New onset or worsening cough or dyspnoea or tachypnoea. New onset or worsening cough or dyspnoea or tachypnoea. Rales or bronchial breath sounds. Rales or bronchial breath sounds. Worsening gas exchange (eg, O2 desaturations (eg, PaO2/FiO2≤240), increased oxygen requirements or increased ventilator demand). Worsening gas exchange (eg, O2 desaturations (eg, PaO2/FiO2≤240), increased oxygen requirements or increased ventilator demand). ARDS: Adult respiratory distress syndrome defined according to the American-European Consensus Conference. All of the following criteria should be met:Acute onset.Arterial hypoxaemia with PaO2/FIO2 ratio <200 (regardless of PEEP level).Bilateral infiltrates detected after chest X-ray or thoracic CT scan.No clinical evidence of left atrial hypertension or pulmonary artery occlusive pressure <18 mm Hg.Compatible risk factors. ARDS: Adult respiratory distress syndrome defined according to the American-European Consensus Conference. All of the following criteria should be met: Acute onset. Acute onset. Arterial hypoxaemia with PaO2/FIO2 ratio <200 (regardless of PEEP level). Arterial hypoxaemia with PaO2/FIO2 ratio <200 (regardless of PEEP level). Bilateral infiltrates detected after chest X-ray or thoracic CT scan. Bilateral infiltrates detected after chest X-ray or thoracic CT scan. No clinical evidence of left atrial hypertension or pulmonary artery occlusive pressure <18 mm Hg. No clinical evidence of left atrial hypertension or pulmonary artery occlusive pressure <18 mm Hg. Compatible risk factors. Compatible risk factors. Pulmonary embolism: the patient experienced a pulmonary embolus in the postoperative period as documented by a V/Q scan, angiogram or spiral CT. Pulmonary embolism: the patient experienced a pulmonary embolus in the postoperative period as documented by a V/Q scan, angiogram or spiral CT. Initial ventilator support >48 hours: the patient was initially ventilated >48 hours in the postoperative period. Ventilator support ends when the endotracheal tube is removed or, if the patient has a tracheostomy tube, until no longer ventilator dependent. Initial ventilator support >48 hours: the patient was initially ventilated >48 hours in the postoperative period. Ventilator support ends when the endotracheal tube is removed or, if the patient has a tracheostomy tube, until no longer ventilator dependent. Reintubation: the patient was reintubated during the initial hospital stay after the initial extubation. This may include patients who have been extubated in the operating room and require intubation in the postoperative period. Reintubation: the patient was reintubated during the initial hospital stay after the initial extubation. This may include patients who have been extubated in the operating room and require intubation in the postoperative period. Tracheostomy: the patient required a tracheostomy in the postoperative period whether performed in the Intensive Care Unit (ICU)or the operation room (OR). A prophylactic mini-tracheostomy performed on the day of operation should not be considered a complication. Tracheostomy: the patient required a tracheostomy in the postoperative period whether performed in the Intensive Care Unit (ICU)or the operation room (OR). A prophylactic mini-tracheostomy performed on the day of operation should not be considered a complication. Pleural effusion: accumulation of excessive fluid in the pleural space. Determining the cause of a pleural effusion is recommended. Pleural effusion: accumulation of excessive fluid in the pleural space. Determining the cause of a pleural effusion is recommended. Empyema: the patient experienced an empyema requiring treatment in the postoperative period; the diagnosis of empyema should be confirmed by thoracentesis. Frank pus or cloudy fluid should be aspirated from the pleural space. The pleural fluid typically has leucocytosis, low pH (<7.20), low glucose (<60 mg/dL), high lactate dehydrogenase, elevated protein and may contain infectious organisms. Empyema: the patient experienced an empyema requiring treatment in the postoperative period; the diagnosis of empyema should be confirmed by thoracentesis. Frank pus or cloudy fluid should be aspirated from the pleural space. The pleural fluid typically has leucocytosis, low pH (<7.20), low glucose (<60 mg/dL), high lactate dehydrogenase, elevated protein and may contain infectious organisms. Unexpected admission to ICU: an unplanned transfer of the patient to the ICU owing to deterioration in the condition of the patient requiring active life support treatment. Unexpected admission to ICU: an unplanned transfer of the patient to the ICU owing to deterioration in the condition of the patient requiring active life support treatment. Subcutaneous emphysema associated with air leak: generally presents as sudden, painless soft tissue swelling, with a predilection for the upper chest, neck and face. Subcutaneous emphysema associated with air leak: generally presents as sudden, painless soft tissue swelling, with a predilection for the upper chest, neck and face. Secondary clinical endpoints Short-term postoperative outcomes:Duration of the pleural drain: the number of days the patient has the pleural drain from surgery to its removal during the hospital stay or in an outpatient setting. Recorded at the time of hospital discharge or at the 30-day postoperative follow-up.Hospital stay: the number of days patient is admitted for the surgery. From the day of admission until discharged. Recorded at the time of hospital discharge.Mortality at hospital discharge: the patient’s vital condition at the end of medical treatment. Recorded at the time of hospital discharge. Short-term postoperative outcomes: Duration of the pleural drain: the number of days the patient has the pleural drain from surgery to its removal during the hospital stay or in an outpatient setting. Recorded at the time of hospital discharge or at the 30-day postoperative follow-up. Duration of the pleural drain: the number of days the patient has the pleural drain from surgery to its removal during the hospital stay or in an outpatient setting. Recorded at the time of hospital discharge or at the 30-day postoperative follow-up. Hospital stay: the number of days patient is admitted for the surgery. From the day of admission until discharged. Recorded at the time of hospital discharge. Hospital stay: the number of days patient is admitted for the surgery. From the day of admission until discharged. Recorded at the time of hospital discharge. Mortality at hospital discharge: the patient’s vital condition at the end of medical treatment. Recorded at the time of hospital discharge. Mortality at hospital discharge: the patient’s vital condition at the end of medical treatment. Recorded at the time of hospital discharge. Long-term postoperative outcomes:Hospital readmission during the 30 days following hospital discharge: record of any clinical situation that requires hospital admission in the centre where the surgical procedure was performed or in another centre. Recorded at the 30-day postoperative follow-up consultation.Mortality at 30 days: the patient’s vital condition 30 days after the surgical procedure. Recorded at the 30-day postoperative follow-up consultation.Mortality at 90 days: the patient’s vital condition 90 days after the surgical procedure. Recorded at the 90-day postoperative follow-up consultation. Long-term postoperative outcomes: Hospital readmission during the 30 days following hospital discharge: record of any clinical situation that requires hospital admission in the centre where the surgical procedure was performed or in another centre. Recorded at the 30-day postoperative follow-up consultation. Hospital readmission during the 30 days following hospital discharge: record of any clinical situation that requires hospital admission in the centre where the surgical procedure was performed or in another centre. Recorded at the 30-day postoperative follow-up consultation. Mortality at 30 days: the patient’s vital condition 30 days after the surgical procedure. Recorded at the 30-day postoperative follow-up consultation. Mortality at 30 days: the patient’s vital condition 30 days after the surgical procedure. Recorded at the 30-day postoperative follow-up consultation. Mortality at 90 days: the patient’s vital condition 90 days after the surgical procedure. Recorded at the 90-day postoperative follow-up consultation. Mortality at 90 days: the patient’s vital condition 90 days after the surgical procedure. Recorded at the 90-day postoperative follow-up consultation. Variables of interest Preoperative information: demographic data, personal history, respiratory function tests, neoadjuvant treatment, culture of bronchial secretions, family or social support, Eurolung1 and Eurolung2. Preoperative information: demographic data, personal history, respiratory function tests, neoadjuvant treatment, culture of bronchial secretions, family or social support, Eurolung1 and Eurolung2. Intraoperative information: surgery performed, tumour, node and metastases staging and definition of residual tumour. Intraoperative information: surgery performed, tumour, node and metastases staging and definition of residual tumour. Information on use of Fissios App tool: total usage time, compliance with respiratory physiotherapy exercises and reading of perioperative medical recommendations. Information on use of Fissios App tool: total usage time, compliance with respiratory physiotherapy exercises and reading of perioperative medical recommendations. Participant timeline Estimated duration of the study Once recruitment is underway at all the centres, the study is expected to last approximately 12 months, with the possibility of an extension of 6 months if necessary (table 1). Table 1Participant timelineRecruitmentAssignationPhase following assignationPhase following assignationPhase following assignationPhase following assignationClose Time −10SurgeryMedical discharge30 days90 days12 months Selection of patients x Informed consent x Assignation x INTERVENTIONS: Fissios App intervention x x x Physiotherapy intervention x x x EVALUATIONS: Patient identification x x Preoperative data x x Operative data x Postoperative data x x x Participant timeline Duration of treatment The minimum duration of the treatment will be 2 weeks over the perioperative period: at least 1 week prior to surgery and 1 week after medical discharge. Performing the treatment for more days will not be penalised in the study. Definition of end of study The study will be concluded when the follow-up of all patients is completed (90 days after surgery of the last randomised patient), all the data are in the database, the statistical analysis is completed and when access to the database is blocked. The end of the study for the patient is when he/she has completed all follow-up visits (90 days after surgery) or withdraws from the study. Sample size The sample size is calculated based on the percentage of postoperative respiratory complications that occurred in 2021 in the thoracic surgery department (24%) of Hospital Clínico San Carlos (HCSC) and the anticipated reduction in the experimental group using the Fissios App tool (12%). To achieve a power of 90%, considering a significance level of 5% and an additional 20% of patients for possible loss to follow-up, a total of 560 patients will be required (280 patients in each group). Recruitment Patients will be recruited in thoracic surgery outpatient departments by thoracic surgeons when recommending the surgery. An explanation of the study will be given along with the invitation to take part. All patients will be invited to take part. There will be no recruitment incentive for either the potential participants or surgeons (hereinafter also referred to as investigators). Allocation Description of randomisation Subjects will be randomly assigned to the experimental or control group in a 1:1 ratio, in blocks of six for each centre. Randomisation will be electronically performed using Fissios Research software. Once the patient has signed the informed consent form and their basic data have been recorded on the eCRF (on the Fissios Research platform), the patient will be automatically randomised according to the defined sequence, and the patient’s treatment arm will be recorded on the eCRF. Blinding (masking) Blinding mechanism This is an open-label type study. As it is the surgeon who will randomise the patients and record their data on the eCRF, there will be no blinding. Because the patients in the experimental group will need to use the Fissios App tool, the participants will know the group they belong to. To reduce bias, the patient randomisation sequence will be performed by staff members who do not form part of the research team and will be kept confidential until the patient is assigned to a group. The informed consent document (online supplemental material 1) and an information sheet (online supplemental material 2) given to the participants will describe the control group and experimental group treatments and their potential effects with the aim of avoiding the generation of strong expectations favouring one method over the other. Data collection Trial procedures and evaluations Data collection methods All data will be collected by qualified thoracic surgeons trained to record all the variables in the database (table 2). The source of clinical information will be the patient’s clinical history kept by each investigator at their centre. An electronic data collection system (on the Fissios Research platform) will be used to record and automatically store the clinical data. The usage data of the Fissios App tool will be automatically stored in the same electronic system. Table 2Activities timelineActivities timelinePreoperative consultation Clinical history, physical examination and additional tests.Determination of the meeting of criteria for recruitment to the study, signing of informed consent.Recruitment of patient on the Fissios Research platform.Patient randomisation.Recording of variables: patient identification; preoperative data.Issue of explanatory material (information sheet) to the patient. Day of surgery Recording of all the “operative data” variables. Day of discharge Recording of the variables: postoperative complications; hospital stay; chest tube duration; outcome at discharge. 30-day follow-up consultation Patient evaluation.Recording of the variables: readmission to any hospital within 30 days of discharge; outcome at 30 days. 90-day follow-up consultation Patient evaluation.Recording of the variable: outcome at 90 days. Activities timeline Clinical history, physical examination and additional tests. Clinical history, physical examination and additional tests. Determination of the meeting of criteria for recruitment to the study, signing of informed consent. Determination of the meeting of criteria for recruitment to the study, signing of informed consent. Recruitment of patient on the Fissios Research platform. Recruitment of patient on the Fissios Research platform. Patient randomisation. Patient randomisation. Recording of variables: patient identification; preoperative data. Recording of variables: patient identification; preoperative data. Issue of explanatory material (information sheet) to the patient. Issue of explanatory material (information sheet) to the patient. Recording of all the “operative data” variables. Recording of all the “operative data” variables. Recording of the variables: postoperative complications; hospital stay; chest tube duration; outcome at discharge. Recording of the variables: postoperative complications; hospital stay; chest tube duration; outcome at discharge. Patient evaluation. Patient evaluation. Recording of the variables: readmission to any hospital within 30 days of discharge; outcome at 30 days. Recording of the variables: readmission to any hospital within 30 days of discharge; outcome at 30 days. Patient evaluation. Patient evaluation. Recording of the variable: outcome at 90 days. Recording of the variable: outcome at 90 days. Data management All data are entered and stored on the Fissios Research platform. Each investigator can access the platform through a unique username and password. The variables will be recorded by a single designated investigator at each centre. Numerical coding is employed for all the variables. Nominal dichotomous qualitative variables concerning the presence/absence of a characteristic are entered as 0 = no, 1 = yes. Nominal qualitative variables of various categories are entered in ascending order from 1, with 0 representing a null value (no response or multiple responses). Quantitative variables are entered as their corresponding numeric value. The translation of these codes is available in the dictionary of variables (online supplemental material 5). Data security information To access data on the Fissios Research platform, a unique username and password will be used which only the corresponding investigator will know. Data will be stored in a back-end server. Google’s Firebase technology will be used, which meets the highest security standards and complies with the EU’s General Data Protection Regulation (GDPR) and the ISO 27001 standard.15 All communications will be performed securely using HTTPS technology, and under no circumstances will personal data of any patient be sent. The patient number on the Fissios Research platform will be randomly assigned and bear no relationship to the patient’s personal data or medical history. Statistical methods Outcomes Descriptive analysis The statistical analysis will be performed by the Methodology Unit for Clinical Research and Epidemiology of HCSC in Madrid, Spain. In the descriptive analysis, the qualitative variables will be presented with their frequency distribution. The quantitative variables will be summarised as the mean and SD. Quantitative variables that show an asymmetric distribution will be summarised as the median and IQR. Calculation of Eurolung1 and Eurolung2 EuroLung1 (morbidity): the risk of postoperative morbidity is calculated using an aggregate score (0–19 points) based on weighted clinical and surgical variables: One point: chronic kidney disease. One point: chronic kidney disease. Two points: coronary artery disease (CAD) and cerebrovascular disease (CVD). Two points: coronary artery disease (CAD) and cerebrovascular disease (CVD). Three points: age >65 years, male sex, thoracotomy approach, extended resections and ppoFEV1<70% Three points: age >65 years, male sex, thoracotomy approach, extended resections and ppoFEV1<70% Based on the cumulative score, patients are stratified into six incremental risk classes (A–F), which have shown significant predictive value for postoperative complications (p<0.0001). EuroLung2 (mortality): this model specifically predicts postoperative mortality through a weighted point system ranging from 0 to 17 points: One point: ppoFEV1<70%, CAD and extended resections. One point: ppoFEV1<70%, CAD and extended resections. Two points: age>65 years and CVD. Two points: age>65 years and CVD. Three points: male sex, thoracotomy approach, body mass index<18.5 kg/m2 and pneumonectomy. Three points: male sex, thoracotomy approach, body mass index<18.5 kg/m2 and pneumonectomy. Patients are subsequently grouped into six incremental mortality risk classes (A–F), with significant prognostic stratification (p<0.0001). Initial comparison of the groups An initial comparison of baseline characteristics will be made between the two study groups. The association between qualitative variables will be evaluated with the chi-squared (χ2) test or Fisher’s exact test if more than 25% of the expected values are under 5. For the quantitative variables, the means will be compared using the Student’s t-test or the Mann-Whitney U test if the quantitative variables do not fit a normal distribution. Analysis of populations Full analysis set (FAS): the primary analysis set for efficacy analyses is defined as the FAS, which will include all randomised participants. Participants will be grouped according to the treatment to which they were randomised. Full analysis set (FAS): the primary analysis set for efficacy analyses is defined as the FAS, which will include all randomised participants. Participants will be grouped according to the treatment to which they were randomised. Per-protocol (PP): The PP analysis set will include all participants in the FAS except for major protocol violators. The PP analysis set will be used for a sensitivity analysis of the primary endpoint. Per-protocol (PP): The PP analysis set will include all participants in the FAS except for major protocol violators. The PP analysis set will be used for a sensitivity analysis of the primary endpoint. Analysis of the aims To study the effectiveness of the Fissios App tool, postoperative complications will be analysed by groups using the chi-squared (χ2) test or Fisher’s exact test if more than 25% of the expected values are under 5. In addition, logistic regression models will be used to ascertain the effect produced and if there is a need to adjust for baseline variables that were not homogeneous between study groups in the initial test. The repeated outcomes measured more than once will be analysed by mixed models which take time into account. With this method we can control the evolution over time. The adverse events (AES) will be summarised by the percentage of occurrences and the 95% CI. A level of statistical significance of 5% will be considered. The analysis will be performed with the IBM SPSS Statistics V.26 and R V.4.2.1 programmes. Data monitoring Formal committee The sponsor will appoint a monitor who will review the source documents to confirm that the data collected in the eCRF are accurate, that the research is performed in accordance with the protocol and that the research team has followed the rules of good clinical practice. Safety/harms The evaluation of safety and harms including definition, management and notification are resumed in online supplemental appendix A. Auditing The investigator and centre will ensure the trial monitors and the competent regulatory authorities have direct access to the source documents for their verification, as well as the centre’s archive and the patient identification list. The centre may be subject to review by the clinical research ethics committee, a safety guarantee audit and/or inspection by the competent regulatory authorities. All documents in the trial master file must be kept for at least 5 years, in accordance with Spanish Law 14/2007 of 3 July, on Biomedical Research. Ethics and dissemination Research ethics approval This protocol and all the Supplementary Material, including the informed consent form, information sheet, and the dictionary for the coding of variables, were reviewed and approved by the Clinical Research and Clinical Trials Unit of HCSC (CRCTU-HCSC), code: 22/310-EC_X. Regarding the scientific content and compliance with prevailing regulations on research involving human subjects, this study complies with the ethics principles for medical research on humans stipulated in the Declaration of Helsinki of the World Medical Association. Informed consent process The investigators will present the study to the potential participants. The main aspects of the study will be orally communicated and the potential participants will also be given an information sheet (online supplemental material 2). The investigators will discuss the study with the potential participants and obtain the signed consent or waiver of informed consent of those who wish to take part (online supplemental material 1). If a trial participant is, because of a disability, unable to sign the consent form, an informed consent form can be signed by an appointed relative or legal representative (online supplemental material 1). Confidentiality In accordance with the provisions of General Data Protection Regulation 2016/679 of the European Parliament and Council, we will notify the participants in the trial that the option to personalise Fissios App is free and not associated with any user’s personal data. By agreeing to take part in this study, no personal data will be processed, only anonymous data relating to the use of and interaction with Fissios App. This application does not necessarily require internet access and does not access personal data from the user’s mobile device. There is no risk of personal information being sent to third parties via the application. All information related to the study will be securely stored at each study centre. All information on trial participants will be stored in files under lock and key in limited access areas. All reports, data collection, process and administrative forms will be identified by means of a unique coded ID to maintain patient confidentiality. All records that contain names or other personal identifiers, such as informed consent forms, will be stored separately from the code-identified study records. The Fissios Research data collection system will be protected with unique username and password access systems personalised for each investigator. The forms, lists, logbooks, appointment books and any other list that links the identification numbers of patients will be stored in a separate locked file in a limited access area. Patient information will not be disclosed outside the study without the patient’s written consent, except as necessary for monitoring by regulatory or governmental agencies. Declaration of interests The authors of this protocol have no conflict of interest to declare. This study will be partially financed through The Spanish Society for Thoracic Surgery (SECT) Foundation 2022 research projects grant (SECT220101), the Dulce López-Fabrizio Facchini 2022 grant, The Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) 2023 research grant in the Thoracic Surgery category and a Medtronic general research grant. These sources of financing have played no role in the study design and will have no impact during its implementation, analysis or data interpretation or on any decision to submit any corresponding manuscript for publication. Access to data All investigators will have access to clean coded data. The study datasets will be hosted on the password-protected Fissios Research web platform. The investigators will have direct access to all data from their own centre. They will also have access to data from other centres on request to the lead researcher and the CRCTU-HCSC. To guarantee confidentiality, no data that could identify study participants will be made available to members of the study team. The trial monitors, auditors and inspectors from the competent authorities will also have access to the data. Dissemination policy Trial results Authorship Any investigator who participates in the conception, design and organisation of the study, in the analysis and interpretation of the results, in the writing of the manuscript or in the management of the editorial process is considered an author. The full study data will not be available to share until the results of the main study are available (table 3). Suggested topics for presentation or publication will be sent to the editorial committee formed by the lead researcher and the CRCTU-HCSC. Table 3Trial resultsGoalPublicationPublish the study protocol. Q1 open access journal. Recruit the first 100 patients. Scientific communication in national and international thoracic surgery meetings.Brief communication in Q1 open access journal. Recruit half of the patients (280). Scientific communication in national and international thoracic surgery meetings.Brief communication in Q1 open access journal. Complete the clinical trial. Original article, Q1 open access journal. Sub analysis of the clinical trial proposed by the research team. Scientific communication in national and international thoracic surgery meetings.Original article, Q1 open access journal Trial results Q1 open access journal. Q1 open access journal. Scientific communication in national and international thoracic surgery meetings. Scientific communication in national and international thoracic surgery meetings. Brief communication in Q1 open access journal. Brief communication in Q1 open access journal. Scientific communication in national and international thoracic surgery meetings. Scientific communication in national and international thoracic surgery meetings. Brief communication in Q1 open access journal. Brief communication in Q1 open access journal. Original article, Q1 open access journal. Original article, Q1 open access journal. Scientific communication in national and international thoracic surgery meetings. Scientific communication in national and international thoracic surgery meetings. Original article, Q1 open access journal Original article, Q1 open access journal If an investigator suggests a topic for possible publication in addition to the main study, the editorial committee will arbitrate the initiative and the order of authorship. The auxiliary study investigator may be deemed principal author of such a study, and the group authorship of the main study should always be referenced using the term ‘FPoC trial group’. Any disputes related to authorship will be resolved by the lead researcher and the CRCTU-HCSC. Study administration Funders The Spanish Society for Thoracic Surgery (SECT) Foundation 2022 research projects grant (SECT220101). The Spanish Society for Thoracic Surgery (SECT) Foundation 2022 research projects grant (SECT220101). The Dulce López-Fabrizio Facchini 2022 grant. The Dulce López-Fabrizio Facchini 2022 grant. The Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) 2023 research grant in the Thoracic Surgery category. The Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) 2023 research grant in the Thoracic Surgery category. Medtronic general research grant. Medtronic general research grant. Limitations A mobile device compatible with Fissios App is required. To address this limitation, the App is available on the two main digital stores, App Store and Google Play Store. Such availability should allow most patients to download and instal the latest version of the App. For users without a compatible smart mobile device, a web version of the App is also available, allowing access from any computer with internet connectivity. The nature of the intervention and the type of device used prevent participants from being blinded. The randomisation of patients and the recording of data on the eCRF is conducted by the surgeon, and participants will be aware of their assigned group. To minimise bias, external staff, independent of the research team, will perform the randomisation sequence, keeping it confidential until the patient’s assignment. The informed consent form (online supplemental material 1) and an information sheet (online supplemental material 2) given to the participants will describe the treatments in the control and experimental groups and their potential effects with the aim of avoiding the generation of strong expectations favouring one method over the other. Numerous protocols for respiratory physiotherapy exist, differing in exercise type, duration, intensity, frequency, supervision and location. To ensure treatment homogeneity, the study will be performed in tertiary hospitals in Spain that jointly offer thoracic surgery and physiotherapy and rehabilitation services. Additionally, a protocol outlining a minimum set of respiratory physiotherapy exercises for the face-to-face sessions will be available (online supplemental material 4) to maximise similarity between treatments in both groups. Perioperative patient management may vary between centres based on medical criteria and available resources. To address this variability, a request will be made for compliance with national and international perioperative guidelines known to all researchers.10 11 The same principle will apply to postoperative respiratory complication definitions, with authors urged to adhere to the definitions established by the ESTS and this protocol to ensure consistency.12 Supplementary material Footnotes Funding: The Spanish Society for Thoracic Surgery (SECT) Foundation 2022 research projects grant (SECT220101). The Dulce López-Fabrizio Facchini 2022 grant. The SEPAR 2023 research grant in the Thoracic Surgery category. Medtronic general research grant. Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Not applicable. Collaborators: Clinical Research and Clinical Trials Unit of HCSC (CRCTU-HCSC). Methodology Unit for Clinical Research and Epidemiology of HCSC. Patient and public involvement: Patients and/or the public were not involved in the design or conduct or reporting or dissemination plans of this research. Data availability statement No data are available. References Associated Data Supplementary Materials Data Availability Statement No data are available.